Association of CMV genomic mutations with symptomatic infection and hearing loss in congenital CMV infection.
Cytomegalovirus (CMV)
Next generation sequencing (NGS)
Sensory neural hearing loss (SNHL)
Viral diversity
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
10 Dec 2019
10 Dec 2019
Historique:
received:
30
08
2019
accepted:
29
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
17
1
2020
Statut:
epublish
Résumé
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection and a leading cause of long-term neurological and sensory sequelae, the most common being sensorineural hearing loss (SNHL). Despite extensive research, clinical or laboratory markers to identify CMV infected children with increased risk for disease have not been identified. This study utilizes viral whole-genome next generation-sequencing (NGS) of specimens from congenitally infected infants to explore viral diversity and specific viral variants that may be associated with symptomatic infection and SNHL. CMV DNA from urine specimens of 30 infants (17 asymptomatic, 13 symptomatic) was target enriched and next generation sequenced resulting in 93% coverage of the CMV genome allowing analysis of viral diversity. Variant frequency distribution was compared between children with symptomatic and asymptomatic cCMV and those with (n = 13) and without (n = 17) hearing loss. The CMV genes UL48A, UL88, US19 and US22 were found to have an increase in nucleotide diversity in symptomatic children; while UL57, UL20, UL104, US14, UL115, and UL35 had an increase in diversity in children with hearing loss. An analysis of single variant differences between symptomatic and asymptomatic children found UL55 to have the highest number, while the most variants associated with SNHL were in the RL11 gene family. In asymptomatic infants with SNHL, mutations were observed more frequently in UL33 and UL20. CMV genomes from infected newborns can be mapped to 93% of the genome at a depth allowing accurate and reproducible analysis of polymorphisms for variant and gene discovery that may be linked to symptomatic and hearing loss outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection and a leading cause of long-term neurological and sensory sequelae, the most common being sensorineural hearing loss (SNHL). Despite extensive research, clinical or laboratory markers to identify CMV infected children with increased risk for disease have not been identified. This study utilizes viral whole-genome next generation-sequencing (NGS) of specimens from congenitally infected infants to explore viral diversity and specific viral variants that may be associated with symptomatic infection and SNHL.
METHODS
METHODS
CMV DNA from urine specimens of 30 infants (17 asymptomatic, 13 symptomatic) was target enriched and next generation sequenced resulting in 93% coverage of the CMV genome allowing analysis of viral diversity.
RESULTS
RESULTS
Variant frequency distribution was compared between children with symptomatic and asymptomatic cCMV and those with (n = 13) and without (n = 17) hearing loss. The CMV genes UL48A, UL88, US19 and US22 were found to have an increase in nucleotide diversity in symptomatic children; while UL57, UL20, UL104, US14, UL115, and UL35 had an increase in diversity in children with hearing loss. An analysis of single variant differences between symptomatic and asymptomatic children found UL55 to have the highest number, while the most variants associated with SNHL were in the RL11 gene family. In asymptomatic infants with SNHL, mutations were observed more frequently in UL33 and UL20.
CONCLUSION
CONCLUSIONS
CMV genomes from infected newborns can be mapped to 93% of the genome at a depth allowing accurate and reproducible analysis of polymorphisms for variant and gene discovery that may be linked to symptomatic and hearing loss outcomes.
Identifiants
pubmed: 31822287
doi: 10.1186/s12879-019-4681-0
pii: 10.1186/s12879-019-4681-0
pmc: PMC6905059
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1046Subventions
Organisme : NIH HHS
ID : R01-DC012661-01
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
mSphere. 2016 May 11;1(3):
pubmed: 27303739
J Gen Virol. 2004 May;85(Pt 5):1301-1312
pubmed: 15105547
J Infect Dis. 2019 Jul 31;220(5):781-791
pubmed: 31050742
J Gen Virol. 1999 Aug;80 ( Pt 8):2183-2191
pubmed: 10466818
J Clin Virol. 2015 Dec;73:101-104
pubmed: 26587788
Science. 1993 Aug 27;261(5125):1179-81
pubmed: 8356453
BMC Genomics. 2013 Jul 24;14:501
pubmed: 23879730
Mol Ecol. 2017 Apr;26(7):1980-1990
pubmed: 27988973
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Chin Med Sci J. 2006 Jun;21(2):69-74
pubmed: 16845790
Clin Rheumatol. 2017 Apr;36(4):863-869
pubmed: 28124759
BMC Genomics. 2013 Nov 19;14:804
pubmed: 24252203
PLoS One. 2011;6(11):e27805
pubmed: 22125625
J Infect Dis. 2011 Oct 1;204(7):1003-7
pubmed: 21881114
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5269-73
pubmed: 291943
J Mol Evol. 1980 Dec;16(2):111-20
pubmed: 7463489
PLoS One. 2014 Apr 22;9(4):e95501
pubmed: 24755734
Arch Virol. 2003 Mar;148(3):547-54
pubmed: 12607105
J Virol. 2015 May 13;89(15):7673-7695
pubmed: 25972543
Front Microbiol. 2014 Dec 18;5:714
pubmed: 25566226
PLoS Pathog. 2015 Oct 20;11(10):e1005227
pubmed: 26484870
Genet Med. 2014 Dec;16(12):945-53
pubmed: 24875298
JAMA. 2010 Apr 14;303(14):1375-82
pubmed: 20388893
Nat Commun. 2013;4:2636
pubmed: 24149915
J Virol. 2015 Jan;89(1):361-72
pubmed: 25320309
Plant Methods. 2010 Sep 28;6:22
pubmed: 20920211
Clin Infect Dis. 2004 Jul 15;39(2):155-61
pubmed: 15307021
Science. 2014 Nov 21;346(6212):987-91
pubmed: 25359852
Open Forum Infect Dis. 2015 Oct 07;2(4):ofv151
pubmed: 26613094
J Virol. 2018 Apr 13;92(9):
pubmed: 29467314
Nat Rev Microbiol. 2017 Mar;15(3):183-192
pubmed: 28090077
Nat Neurosci. 2016 Apr;19(4):571-7
pubmed: 26974950
J Infect Dis. 2017 Jun 1;215(11):1673-1683
pubmed: 28368496
PLoS Pathog. 2011 May;7(5):e1001344
pubmed: 21625576
Intervirology. 2014;57(6):384-92
pubmed: 25382636
Traffic. 2011 Oct;12(10):1444-56
pubmed: 21689255
J Virol. 2015 Jan;89(1):833-43
pubmed: 25355888
Clin Infect Dis. 2010 Jul 1;51(1):33-41
pubmed: 20504230
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4120-8
pubmed: 26150505
Nat Biotechnol. 2009 Feb;27(2):182-9
pubmed: 19182786
Cell. 2012 Mar 2;148(5):873-85
pubmed: 22385957
Arch Virol. 2012 Apr;157(4):703-11
pubmed: 22270759
PLoS Pathog. 2014 Oct 09;10(10):e1004377
pubmed: 25299639
J Clin Virol. 2001 Apr;21(1):75-9
pubmed: 11255100
PLoS Pathog. 2017 Aug 30;13(8):e1006601
pubmed: 28854233
J Clin Microbiol. 2013 Dec;51(12):4266-9
pubmed: 24108608
Pediatrics. 2017 Feb;139(2):
pubmed: 28049114
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5693-5698
pubmed: 30819890
Blood. 2012 May 24;119(21):4908-18
pubmed: 22496149
PLoS One. 2014 Sep 30;9(9):e108018
pubmed: 25268349
Nat Genet. 2015 Sep;47(9):1067-72
pubmed: 26258849
Genome Announc. 2017 Jan 19;5(3):
pubmed: 28104650
J Med Virol. 1998 May;55(1):75-81
pubmed: 9580889
PLoS Genet. 2013;9(9):e1003735
pubmed: 24086142
J Clin Virol. 2013 Sep;58(1):271-5
pubmed: 23806667
Hepatology. 2015 Jan;61(1):56-65
pubmed: 25123381
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
Arch Ophthalmol. 1998 Feb;116(2):178-85
pubmed: 9488269
Pediatr Infect Dis J. 2013 Oct;32(10):1050-4
pubmed: 23694837
J Virol. 2016 Mar 28;90(8):3929-43
pubmed: 26842472
J Virol. 2017 Feb 14;91(5):
pubmed: 27974561
Nat Rev Genet. 2014 Feb;15(2):121-32
pubmed: 24434847
J Virol. 2016 Jan 06;90(7):3355-65
pubmed: 26739054
Mol Ecol. 2016 Jan;25(1):403-13
pubmed: 26211679
N Engl J Med. 2011 Jun 2;364(22):2111-8
pubmed: 21631323